Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer
Completed
- Conditions
- Prostate CancerBone Loss
- Registration Number
- NCT00199537
- Lead Sponsor
- Lawson Health Research Institute
- Brief Summary
Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is expected that men undergoing androgen blockade will experience accelerated bone loss.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 25
Inclusion Criteria
- Men
- Age of 40 years or greater
- Diagnosis of advanced prostate cancer (ie: prostate-specific antigen [PSA] less than 25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing hormone [LHRH] therapy)
- Willing and able to consent
Exclusion Criteria
- Metastatic disease to bone
- Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant)
- Renal failure (serum creatinine > 200 umol/L)
- Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis)
- Factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty)
- Cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial
- Gastrointestinal (GI) pathology (eg. malabsorption syndrome)
- Parathyroid disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie androgen blockade-induced bone loss in prostate cancer patients?
How does androgen blockade compare to other adjuvant therapies in preventing prostate cancer-related bone loss?
What biomarkers are associated with accelerated bone loss during androgen blockade for prostate cancer?
What are the most effective strategies for managing bone loss in prostate cancer patients on androgen blockade?
Are there combination therapies or alternative drugs that mitigate bone loss in prostate cancer patients undergoing androgen blockade?
Trial Locations
- Locations (1)
Urology Clinic & Prostate Centre, St. Joseph's Hospital, St. Joseph's Health Care London
🇨🇦London, Ontario, Canada
Urology Clinic & Prostate Centre, St. Joseph's Hospital, St. Joseph's Health Care London🇨🇦London, Ontario, Canada